Company News »

NeuroMetrix Announces First Shipments of QuellTM Wearable Pain Relief Device

Business Wire
Share on StockTwits
Published on

NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has started shipping Quell wearable pain relief devices out of its production and fulfillment facility in Woburn, MA. The initial shipments are directed to leading doctors and thought leaders in chronic pain. The Company anticipates that it will start fulfilling orders in late May that were placed through its pre-order campaign on the Indiegogo platform. The Company expects to clear the remaining backorders and begin ongoing commercial shipments for new orders in June. The Company has an order backlog of about 2000 Quell devices.

Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide pain relief. The device is designed for people with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia, and pain associated with osteoarthritis. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device have the option of using their smartphone to automatically track and personalize their pain therapy through the Quell Relief app, an updated version of which was released this week in the Apple app store.

“Initiating shipments of Quell represents a significant milestone for NeuroMetrix. This is an important step in completing our transformation from a traditional medical device company to one focused on the growing consumer healthcare market,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “Our employees have worked very hard to achieve this goal, and we are justifiably proud of this important achievement. We now look forward to growing Quell into a large and successful consumer healthcare brand.”

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements that involve a number of known and unknown risks, uncertainties and other factors that may cause such forward-looking statements not to be realized. We believe these factors include but are not limited to those described under “Risk Factors” in our Annual Report on Form 10-K, as such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our Annual Report on Form 10-K and other filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit www.QuellRelief.com and www.NeuroMetrix.com.

Share on StockTwits